上海复旦张江生物医药股份有限公司关于持股5%以上股东减持股份结果公告

Group 1 - The major shareholder, Yang Zongmeng, held 64,009,773 shares, representing 6.18% of the total share capital before the reduction plan [2] - Yang Zongmeng planned to reduce his holdings by up to 10,365,721 shares, which is no more than 1.00% of the total share capital, due to personal funding needs [3] - The reduction was successfully completed between November 26, 2025, and January 12, 2026, with a total of 10,365,721 shares sold, matching the planned reduction [4]